Biogen Inc. (BGEN)
Matthew Geller of Oppenheimer & Co. raised his rating on the Cambridge, Mass., company to "buy" and added it to Oppenheimer's "recommended" list. Geller said that BGEN's beta interferon is superior to Chiron Corp.'s Betaseron for multiple sclerosis, with a better dosing schedule, fewer side effects and a statistically significant impact on progression of the disease.